Wellington Management Group LLP Grows Position in KalVista Pharmaceuticals, Inc. $KALV

Wellington Management Group LLP lifted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 2.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,268 shares of the specialty pharmaceutical company’s stock after buying an additional 3,405 shares during the period. Wellington Management Group LLP owned approximately 0.25% of KalVista Pharmaceuticals worth $1,457,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers lifted its position in KalVista Pharmaceuticals by 3.4% during the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock valued at $611,000 after purchasing an additional 1,762 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 3,767 shares in the last quarter. Earned Wealth Advisors LLC bought a new stake in KalVista Pharmaceuticals during the first quarter worth approximately $44,000. Wells Fargo & Company MN grew its stake in shares of KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company’s stock valued at $171,000 after buying an additional 4,543 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the last quarter.

KalVista Pharmaceuticals Trading Down 0.4%

Shares of KalVista Pharmaceuticals stock opened at $13.46 on Monday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.32. The stock has a market cap of $677.58 million, a PE ratio of -3.65 and a beta of -0.10. The company has a 50-day moving average of $13.50 and a two-hundred day moving average of $12.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($2.86). During the same period last year, the firm earned ($1.07) EPS. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the transaction, the insider owned 119,841 shares in the company, valued at approximately $1,584,298.02. The trade was a 2.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the business’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer owned 369,595 shares in the company, valued at $5,798,945.55. This represents a 8.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,710 shares of company stock worth $880,764 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

KALV has been the topic of several research analyst reports. HC Wainwright increased their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. Leerink Partners increased their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, July 7th. Finally, JMP Securities raised their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a “market outperform” rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.29.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).